Novoheart Profiled on CBC’s Flagship News Program ‘The National’
VANCOUVER, BRITISH COLUMBIA–(Marketwired – Dec. 11, 2017) - Novoheart (“Novoheart” or the “Company”) (TSX VENTURE:NVH), a global stem cell biotechnology company, is pleased to announce that an in-depth feature on the company and its technology was broadcast on Friday, December 8th on CBC News, Canada’s largest news broadcaster.
The Novoheart feature appeared on ‘The National’ – CBC’s flagship television news program which is broadcast across Canada – and was followed up with a detailed online article, published on CBC.ca. It profiled the team and scientific developments behind the company’s state-of-the-art human heart constructs and the major advantages its MyHeart™ platform offers global drug developers in providing accurate preclinical testing with lab-grown human heart tissues and chambers.
The program can be viewed in full here – https://www.youtube.com/watch?v=n0vgDRvXCOU
The online story can be viewed here – http://www.cbc.ca/news/business/novoheart-stem-cells-tiny-hearts-drug-testing-1.4432367
Novoheart is a global stem cell biotechnology company pioneering an array of next-generation human heart tissue prototypes. It is the first company in the world to have engineered miniature living human heart pumps that can revolutionize drug discovery, helping to save time and money for developing new therapeutics.
Also known as ‘human heart-in-a-jar’, Novoheart’s bioartificial human heart constructs are created using state-of-the-art stem cell and bioengineering approaches, and are utilized by drug developers for accurate preclinical testing as to the effectiveness and safety of new drugs, maximizing the successes in drug discovery whilst minimizing costs and harm caused to patients.
The Company is listed on the TSX Venture Exchange (the “TSXV”) under the symbol “NVH”.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
Information set forth in this news release may involve forward-looking statements under applicable securities laws. Forward-looking statements are statements that relate to future, not past, events. In this context, forward-looking statements often address expected future business and financial performance, and often contain words such as “anticipate”, “believe”, “plan”, “estimate”, “expect”, and “intend”, statements that an action or event “may”, “might”, “could”, “should”, or “will” be taken or occur, or other similar expressions. All statements, other than statements of historical fact, included herein including, without limitation; statements about the Company’s future plans, its goals and expectations, and the potential applications of its MyHeart™ platform are forward-looking statements. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the risks identified in the management discussion and analysis section of Novoheart Holdings Inc.’s interim and most recent annual financial statement or other reports and filings with the TSX Venture Exchange and applicable Canadian securities regulators. Forward-looking statements are made based on management’s beliefs, estimates and opinions on the date that statements are made and the respective companies undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable securities laws. Investors are cautioned against attributing undue certainty to forward-looking statements.
Babak Pedram, Investor Relations
Virtus Advisory Group
For media enquiries or interviews, please contact:
Josh Stanbury, Media Relations